Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 10/20 | 0.49 |
| ▸ | CES2 | O00748 | 4/20 | 0.43 |
| ▸ | CES1 | P23141 | 4/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10061120 | 0.81 | RIPK1 (0.42) | RIPK1CES2CES1GPR84 | |
| SCHEMBL2652556 | 0.80 | RIPK1 (0.44) | RIPK1CES2CES1GPR84 | |
| SCHEMBL10026826 | 0.79 | RIPK1 (0.49) | RIPK1CES2CES1 | |
| SCHEMBL14378238 | 0.79 | RIPK1 (0.42) | RIPK1CES2CES1 | |
| SCHEMBL14614705 | 0.78 | SIGMAR1 (0.37) | RIPK1 | |
| SCHEMBL18930045 | 0.78 | RIPK1 (0.40) | RIPK1CES2CES1PKMTAAR1 | |
| SCHEMBL18133370 | 0.78 | RIPK1 (0.37) | RIPK1CES2CES1PKMTAAR1 | |
| SCHEMBL10224909 | 0.78 | RIPK1 (0.33) | RIPK1 | |
| SCHEMBL6634488 | 0.77 | HDAC3 (0.39) | RIPK1CES2CES1TAAR1 | |
| SCHEMBL24311470 | 0.76 | KCNH2 (0.36) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183218-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-11034695-B2 | Dopamine-β-hydroxylase inhibitors | BIAL—Portela & Cᵃ, S.A. (PT) | 2021-06-15 | — | — | US | disclosed |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2021-04-13 | — | — | US | disclosed |
| US-20200397774-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE HOLDINGS CORPORATION | 2020-12-24 | — | — | US | disclosed |
| US-10807971-B2 | Pyrrolidinone compounds | ELI LILLY AND COMPANY (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200207726-A1 | INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2020-07-02 | — | — | US | disclosed |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200181148-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL-PORTELA & CA, S.A. (PT) | 2020-06-11 | — | — | US | disclosed |
| WO-2020025658-A1 | PESTICIDALLY-ACTIVE BICYCLIC HETEROAROMATIC COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2020-02-06 | — | — | WO | disclosed |
| US-20190345144-A1 | PYRROLIDINONE COMPOUNDS | ELI LILLY AND COMPANY | 2019-11-14 | — | — | US | disclosed |
| US-20170246157-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2017-08-31 | — | — | US | disclosed |
| US-20120052685-A1 | SILICON-CONTAINING FILM-FORMING COMPOSITION, SILICON-CONTAINING FILM-FORMED SUBSTRATE, AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-01 | — | — | US | disclosed |
| US-7888376-B2 | Cholesteryl ester transfer protein (CETP) inhibitors; atherosclerosis and cardiovascular diseases; N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-4-(trifluoromethyl)thiazol-2-amine; Alzheimer's, atherosclerosis, venous thrombosis, peripheral vascular disease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-7601728-B2 | Bicyclic pyrrole derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20090192129-A1 | BICYCLIC PYRROLE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090149483-A1 | BICYCLIC PYRROLE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20090054423-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. | 2009-02-26 | — | — | US | disclosed |
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1594878-B1 | AVERMECTIN MONOSACCHARIDE DERIVATIVES HAVING PESTICIDAL PROPERTIES | MERIAL LTD (GB) | 2008-06-04 | — | — | EP | disclosed |
| EP-1218348-B1 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMA (US) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183218-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | RIPK1 2567/4885CES2 852/4885CES1 1298/4885 |
| US-20200207726-A1 | INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | RORA, RORC, RORB | RIPK1 507/4885CES2 3493/4885CES1 1532/4885 |
| US-20190345144-A1 | PYRROLIDINONE COMPOUNDS | NPY4R, NPY2R, NPY5R | RIPK1 2509/4885CES2 2638/4885CES1 1455/4885 |
| US-10807971-B2 | Pyrrolidinone compounds | NPY4R, NPY2R, NPY5R | RIPK1 2509/4885CES2 2638/4885CES1 1455/4885 |
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DPP4, DPP7, DPP3 | RIPK1 3790/4885CES2 127/4885CES1 33/4885 |
| US-20090192129-A1 | BICYCLIC PYRROLE DERIVATIVES | DPP4, DPP7, DPP3 | RIPK1 3223/4885CES2 170/4885CES1 40/4885 |
| US-20200397774-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | RIPK1 382/4885CES2 4709/4885CES1 2884/4885 |
| US-20090149483-A1 | BICYCLIC PYRROLE DERIVATIVES | DPP4, DPP7, DPP3 | RIPK1 3223/4885CES2 170/4885CES1 40/4885 |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | DBH, SLC6A3, SLC6A2 | RIPK1 4832/4885CES2 162/4885CES1 226/4885 |
| US-20200181148-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, MAOB, SLC6A3 | RIPK1 4582/4885CES2 199/4885CES1 438/4885 |
| US-20090054423-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | FFAR1, HCAR1, GPR119 | RIPK1 2744/4885CES2 1278/4885CES1 179/4885 |
| US-20170246157-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | RIPK1 382/4885CES2 4709/4885CES1 2884/4885 |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | JAK1, JAK2, JAK3 | RIPK1 382/4885CES2 4709/4885CES1 2884/4885 |
| US-11034695-B2 | Dopamine-β-hydroxylase inhibitors | DBH, SLC6A3, COMT | RIPK1 4605/4885CES2 221/4885CES1 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.